Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
Status:
Withdrawn
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
The main objective of the trial to determine if the combination of apalutamide with 6 months
of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited
high-risk, localized prostate cancer receiving primary radiation therapy (RT) results in an
improvement of disease-free survival (DFS) evaluated by the treating physician, in comparison
to the combination of radiation and androgen deprivation therapy without the addition of
apalutamide.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC